Jiangsu Yahong Meditech Co Ltd - Class A

NEW
SHSE:688176 (China)   Class A
Â¥ 13.03 -1.4 (-9.7%) Jul 17
At Loss
P/B:
5.07
Market Cap:
Â¥ 7.46B ($ 1.10B)
Enterprise V:
Â¥ 6.41B ($ 947.08M)
Volume:
42.88M
Avg Vol (2M):
16.62M
Trade In:
Volume:
42.88M
At Loss
Avg Vol (2M):
16.62M

Business Description

Description
Jiangsu Yahong Meditech Co Ltd is engaged in the field of urogenital system tumors and other diseases.
Name Current Vs Industry Vs History
Cash-To-Debt
3.87
Equity-to-Asset
0.74
Debt-to-Equity
0.24
Debt-to-EBITDA
-0.79
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
6.99
Distress
Grey
Safe
Beneish M-Score
-2.65
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
41.79
9-Day RSI
52.42
14-Day RSI
55.17
3-1 Month Momentum %
-26.87
6-1 Month Momentum %
-24.2
12-1 Month Momentum %
-14.71

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
4.07
Quick Ratio
4.03
Cash Ratio
3.44
Days Inventory
63.71
Days Sales Outstanding
110.61
Days Payable
200.99

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-0.1
Shareholder Yield %
-2.26
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Jiangsu Yahong Meditech Co Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ¥) 287.106
EPS (TTM) (Â¥) -0.79
Beta 1.2126
3-Year Sharpe Ratio -0.03
3-Year Sortino Ratio -0.05
Volatility % 48.46
14-Day RSI 55.17
14-Day ATR (Â¥) 1.053194
20-Day SMA (Â¥) 11.9255
12-1 Month Momentum % -14.71
52-Week Range (Â¥) 8.93 - 18.11
Shares Outstanding (Mil) 572.19

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Jiangsu Yahong Meditech Co Ltd Filings

Filing Date Document Date Form
No Filing Data

Jiangsu Yahong Meditech Co Ltd Stock Events

Financials Calendars
Event Date Price (Â¥)
No Event Data

Jiangsu Yahong Meditech Co Ltd Frequently Asked Questions

What is Jiangsu Yahong Meditech Co Ltd(SHSE:688176)'s stock price today?
The current price of SHSE:688176 is ¥13.03. The 52 week high of SHSE:688176 is ¥18.11 and 52 week low is ¥8.93.
When is next earnings date of Jiangsu Yahong Meditech Co Ltd(SHSE:688176)?
The next earnings date of Jiangsu Yahong Meditech Co Ltd(SHSE:688176) is .
Does Jiangsu Yahong Meditech Co Ltd(SHSE:688176) pay dividends? If so, how much?
Jiangsu Yahong Meditech Co Ltd(SHSE:688176) does not pay dividend.

Press Release

Subject Date
Global Experts Convene at IFCPC 2026: Topical Photodynamic Therapy Reshapes the Individualized Management Paradigm for Cervical Precancerous Lesions 2026-07-17
Asieris' CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions 2026-03-03
Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program 2025-01-06
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study 2024-03-18
Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion 2024-01-08
APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia 2023-12-24
Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress 2023-10-12
The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint 2023-09-20
Asieris' New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC 2023-09-14
Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer 2023-09-13
10/Page